Clinigen Takes Aim At Unlicensed-To-Licensed Strategy With Quantum Buy
Executive Summary
Extending its business in continental Europe, in niche generics and in the further development of unlicensed medicines are some of the drivers of Clinigen's latest proposed acquisition.
You may also be interested in...
Deal Watch: AstraZeneca Offloads US Anesthesiology Portfolio To Aspen
Merck adds to its immuno-oncology R&D heft with purchase of Rigontec, while Allergan will collaborate with Lyndra to produce once-weekly drugs for Alzheimer’s disease.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.